For this special edition of Oncology Today, I met with Dr Srdan Verstovsek from the MD Anderson Cancer Center in Houston, Texas, to discuss recently published and emerging research in the management of myeloproliferative neoplasms.

CME information and select publications here.

For this special edition of Oncology Today, I met with Dr Pasi Jänne from the Dana-Farber Cancer Institute in Boston, Massachusetts to discuss recently published and emerging research in the management of EGFR mutation-positive non-small cell lung cancer.

CME information and select publications here.

For this special edition of Oncology Today, I met with Dr Nikhil Munshi from the Dana-Farber Cancer Institute in Boston to discuss recently published and emerging research on the use of CAR T-cell therapy in multiple myeloma.

CME information and select publications here.

For this special edition of Oncology Today, I met with Dr Petros Grivas from the Fred Hutchinson Cancer Research Center in Seattle to discuss recently published and emerging research on the use of immunotherapy in the management of urothelial bladder carcinoma.

CME information and select publications here.

For this special edition of Oncology Today, I met with Dr Nikhil Khushalani from the Moffitt Cancer Center in Tampa, Florida, to discuss recently published and emerging research including the use of the immune checkpoint inhibitors cemiplimab and pembrolizumab in the management of cutaneous squamous cell carcinoma.

CME information and select publications here.

For this special edition of Oncology Today, I met with Dr Charles Rudin from Memorial Sloan Kettering Cancer Center in New York to discuss recently published and emerging research in the management of small cell lung cancer (SCLC), including the recent approval of lurbinectedin as second-line treatment for extensive-stage SCLC.

CME information and select publications here.

For this special edition of Oncology Today, Dr Neil Love discusses recently published and emerging research in follicular lymphoma with Drs Carla Casulo from the University of Rochester Wilmot Cancer Center and John P Leonard from the Weill Medical College of Cornell.

CME information and select publications here.

Featuring a roundtable discussion with Drs Axel Grothey and Michael J Overman moderated by Neil Love, MD.

CME information and select publications here.

Dr John Heymach from the MD Anderson Cancer Center discusses the role of anti-angiogenic agents in NSCLC and the status of clinical research for and treatment of lung cancer at MD Anderson during the COVID-19 pandemic.

RTP Lung Cancer Summit: https://www.researchtopractice.com/LungCancerSummit20/

Additional Resources

Is it worthwhile to treat pancreatic cancer? Dr Michael Pishvaian from Johns Hopkins University discusses the use of the PARP inhibitor olaparib and other new developments in the disease.

Additional Resources